Proposed Class Action Settlement for Greenlight Biosciences Investors Announced
On April 10, 2026, legal representatives from Monteverde & Associates, Kahn Swick & Foti, and Levi & Korsinsky announced a proposed settlement for shareholders involved in the Greenlight Biosciences Holdings, PBC class action lawsuit. This notice pertains to all record and beneficial holders of Greenlight's common stock who held shares during the recent merger-related tender offer with Fall Line Capital, which occurred from June 21 to July 20, 2023.
The class action lawsuit, officially titled In re GreenLight Bio Merger Stockholder Litigation, is currently pending in the Delaware Court of Chancery, with Lead Civil Action Number 2024-1020-KSJM. The case arose following the exchange of Greenlight shares for $0.30 per share related to the merger closure on July 24, 2023. The settlement proposal includes $2 million set aside for shareholders impacted by the merger.
The details of the court hearing scheduled for June 29, 2026, at 1:30 PM are essential for shareholders looking to understand their rights and obligations. This hearing will determine various aspects, including whether the action may be maintained as a non-opt-out class action, the final certification of the class, and whether the proposed settlement is fair and adequate for the represented shareholders.
This proposed settlement is critical for all individuals who held Greenlight common stock during the designated period and may have claims relating to the transaction. The outcome of this case could significantly affect the financial interests of class members.
If you held Greenlight shares during the relevant timeframe and did not receive the Notice of Pendency of Stockholder Class Action and Proposed Settlement, it is advised to reach out to RG/2 Claims Administration LLC at P.O. Box 59479, Philadelphia, PA 19102-9479, or via telephone at 1-866-742-4955. Alternatively, you can access the information online at www.rg2claims.com/greenlight.html.
Shareholders identified as class members must submit a Proof of Claim and Release to participate in the distribution of the Net Settlement Fund. This submission must be postmarked no later than July 29, 2026. Online submissions are also permissible by the same date. It’s crucial for investors to ensure they establish their entitlement to any recovery stemming from the lawsuit.
If you are a class member and wish to object to the proposed settlement, you should present your case at the upcoming Settlement Hearing. To do so, written objections must be filed with the Register in Chancery by June 15, 2026. This includes providing your details, stating your objection, and explaining your reasoning alongside any evidence.
For any questions, class members are encouraged to contact the Co-Lead Counsel. Reach out to the respective firms:
1. Monteverde & Associates PC – Juan E. Monteverde, located in the Empire State Building, New York.
2. Kahn Swick & Foti, LLC – Michael J. Palestina in New Orleans, Louisiana.
3. Levi & Korsinsky, LLP – Donald J. Enright, based in Washington, D.C.
As a plaintiff or potential member of the class, it is essential to stay informed of any updates regarding this settlement and the court's proceedings, as it could significantly influence your investment in Greenlight Biosciences. The settlement not only addresses the financial ramifications but also stands as a testament to shareholder rights and corporate governance.
Overview of the Class Action and Settlement
The class action lawsuit, officially titled In re GreenLight Bio Merger Stockholder Litigation, is currently pending in the Delaware Court of Chancery, with Lead Civil Action Number 2024-1020-KSJM. The case arose following the exchange of Greenlight shares for $0.30 per share related to the merger closure on July 24, 2023. The settlement proposal includes $2 million set aside for shareholders impacted by the merger.
The details of the court hearing scheduled for June 29, 2026, at 1:30 PM are essential for shareholders looking to understand their rights and obligations. This hearing will determine various aspects, including whether the action may be maintained as a non-opt-out class action, the final certification of the class, and whether the proposed settlement is fair and adequate for the represented shareholders.
Implications for Shareholders
This proposed settlement is critical for all individuals who held Greenlight common stock during the designated period and may have claims relating to the transaction. The outcome of this case could significantly affect the financial interests of class members.
If you held Greenlight shares during the relevant timeframe and did not receive the Notice of Pendency of Stockholder Class Action and Proposed Settlement, it is advised to reach out to RG/2 Claims Administration LLC at P.O. Box 59479, Philadelphia, PA 19102-9479, or via telephone at 1-866-742-4955. Alternatively, you can access the information online at www.rg2claims.com/greenlight.html.
Claiming Your Distribution
Shareholders identified as class members must submit a Proof of Claim and Release to participate in the distribution of the Net Settlement Fund. This submission must be postmarked no later than July 29, 2026. Online submissions are also permissible by the same date. It’s crucial for investors to ensure they establish their entitlement to any recovery stemming from the lawsuit.
Objecting to the Settlement
If you are a class member and wish to object to the proposed settlement, you should present your case at the upcoming Settlement Hearing. To do so, written objections must be filed with the Register in Chancery by June 15, 2026. This includes providing your details, stating your objection, and explaining your reasoning alongside any evidence.
Legal Counsel and Further Assistance
For any questions, class members are encouraged to contact the Co-Lead Counsel. Reach out to the respective firms:
1. Monteverde & Associates PC – Juan E. Monteverde, located in the Empire State Building, New York.
2. Kahn Swick & Foti, LLC – Michael J. Palestina in New Orleans, Louisiana.
3. Levi & Korsinsky, LLP – Donald J. Enright, based in Washington, D.C.
As a plaintiff or potential member of the class, it is essential to stay informed of any updates regarding this settlement and the court's proceedings, as it could significantly influence your investment in Greenlight Biosciences. The settlement not only addresses the financial ramifications but also stands as a testament to shareholder rights and corporate governance.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.